These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31072919)

  • 1. Activin A: a novel urinary biomarker of renal impairment in multiple myeloma.
    Iriuchishima H; Maeshima A; Takahashi S; Ishizaki T; Yokohama A; Tsukamoto N; Saitoh T; Murakami H; Handa H
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 31072919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary Activin A is a novel biomarker reflecting renal inflammation and tubular damage in ANCA-associated vasculitis.
    Takei Y; Takahashi S; Nakasatomi M; Sakairi T; Ikeuchi H; Kaneko Y; Hiromura K; Nojima Y; Maeshima A
    PLoS One; 2019; 14(10):e0223703. PubMed ID: 31613925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Urinary Activin A as a Novel Biomarker Reflecting the Severity of Acute Kidney Injury.
    Takahashi S; Nakasatomi M; Takei Y; Ikeuchi H; Sakairi T; Kaneko Y; Hiromura K; Nojima Y; Maeshima A
    Sci Rep; 2018 Mar; 8(1):5176. PubMed ID: 29581558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary NGAL for the diagnosis of the renal injury from multiple myeloma.
    Du W; Shen T; Li H; Liu Y; He L; Tan L; Hu M
    Cancer Biomark; 2017; 18(1):41-46. PubMed ID: 27814274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary N-acetyl-beta-D-glucosaminidase as an indicator of tubular damage in multiple myeloma.
    Coward RA; DeLamore IW; Mallick NP; Robinson LE
    Clin Chim Acta; 1984 Apr; 138(3):293-8. PubMed ID: 6426824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of renal function in patients with multiple myeloma: the role of urinary proteins.
    Corso A; Serricchio G; Zappasodi P; Klersy C; Bosoni T; Moratti R; Castagnola C; Lazzarino M; Pagnucco G; Bernasconi C
    Ann Hematol; 1999 Aug; 78(8):371-5. PubMed ID: 10460351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.
    Papassotiriou GP; Kastritis E; Gkotzamanidou M; Christoulas D; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Roussou M; Margeli A; Papassotiriou I; Dimopoulos MA; Terpos E
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):29-35. PubMed ID: 26632077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
    Terpos E; Christoulas D; Kastritis E; Bagratuni T; Gavriatopoulou M; Roussou M; Papatheodorou A; Eleutherakis-Papaiakovou E; Kanellias N; Liakou C; Panagiotidis I; Migkou M; Kokkoris P; Moulopoulos LA; Dimopoulos MA
    Blood Cancer J; 2016 Oct; 6(10):e482. PubMed ID: 27716740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Exploration of early assessment of renal impairment in multiple myeloma].
    Zhong Y; Yuan ZG; Fu WJ; Zhou F; Zhang CY; Zhang WH; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):819-22. PubMed ID: 23384902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Significance of low molecular weight urinary protein for assessment of early renal damage in patients with multiple myeloma].
    Liu SJ; Zhai YP; Yu YP; Liu HN; Li F; Song P; Zhou XG; An ZM; Shao JJ; Yang XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):410-4. PubMed ID: 23628043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?
    Woziwodzka K; Małyszko J; Koc-Żórawska E; Żórawski M; Dumnicka P; Jurczyszyn A; Batko K; Mazur P; Banaszkiewicz M; Krzanowski M; Gołasa P; Małyszko JA; Drożdż R; Krzanowska K
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Urinary N-acetyl-beta-D-glucosaminidase and gamma-glutamyl-transpeptidase activities for evaluation of renal disturbance in patients with multiple myeloma].
    Nishimura K; Kawada M; Suehiro T; Yamano T; Hashimoto K
    Nihon Jinzo Gakkai Shi; 1992 Oct; 34(10):1087-94. PubMed ID: 1363243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Activin A, Kidney Fibrosis, and Adverse Events.
    Tsai MT; Ou SM; Lee KH; Lin CC; Li SY
    Clin J Am Soc Nephrol; 2024 Feb; 19(2):169-177. PubMed ID: 37983094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
    Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
    Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological characteristics of patients with paraproteinemia and renal damage.
    Tang X; Wan F; Yu J; Li X; Yang R; Zhu B
    Eur J Med Res; 2021 Jul; 26(1):68. PubMed ID: 34217367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():478-87. PubMed ID: 24319222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percentage of urinary albumin excretion and serum-free light-chain reduction are important determinants of renal response in myeloma patients with moderate to severe renal impairment.
    Sugihara H; Chihara D; Seike K; Fukumoto K; Fujisawaa M; Suehara Y; Nishida Y; Takeuchi M; Matsue K
    Blood Cancer J; 2014 Aug; 4(8):e235. PubMed ID: 25083819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary Activin A: A Novel Biomarker for Human Acute Kidney Injury.
    Nagayama I; Maeshima A; Nagata D
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.